A. BİLİCİ Et Al. , "Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer," Asian Pacific Journal of Cancer Prevention , vol.15, no.20, pp.8661-8666, 2014
BİLİCİ, A. Et Al. 2014. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer. Asian Pacific Journal of Cancer Prevention , vol.15, no.20 , 8661-8666.
BİLİCİ, A., Selcukbiricik, F., Demir, N., Ustaalioglu, B. B. O., Dikilitas, M., & YILDIZ, Ö., (2014). Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer. Asian Pacific Journal of Cancer Prevention , vol.15, no.20, 8661-8666.
BİLİCİ, Ahmet Et Al. "Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer," Asian Pacific Journal of Cancer Prevention , vol.15, no.20, 8661-8666, 2014
BİLİCİ, Ahmet Et Al. "Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer." Asian Pacific Journal of Cancer Prevention , vol.15, no.20, pp.8661-8666, 2014
BİLİCİ, A. Et Al. (2014) . "Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer." Asian Pacific Journal of Cancer Prevention , vol.15, no.20, pp.8661-8666.
@article{article, author={Ahmet BİLİCİ Et Al. }, title={Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2- negative advanced gastric cancer}, journal={Asian Pacific Journal of Cancer Prevention}, year=2014, pages={8661-8666} }